CA-HAI-SOLUTIONS
22.5.2023 12:01:33 CEST | Business Wire | Press release
Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access. The partnership combines Intellego's patented ultraviolet-sensitive ink as an indicator component in HAI Solutions' QIKcap™ technology to offer visible and verifiable IV port protection and provide confidence that the needle-free connector has been disinfected.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005235/en/
The QIKcap (TM) disposable IV luer access cap with Intellego’s chromatic ink changes from yellow to pink, providing visible indication that a sufficient dose of germicidal energy has been delivered by HAI Solutions QIKcap (TM) handheld UV-C disinfection device. (Photo: Business Wire)
The QIKcap Disinfection Device™ is a patented, handheld UV-C tool that is designed to irradiate the surface of an intravenous connector and intravenous access points to prevent microbial ingress. The specialized luer cap, known as QIKcap™, incorporates Intellego’s proprietary ink. When the QIKcap is irradiated with the UV-C handheld device, the cap changes color from yellow to pink, providing visible indication that a sufficient dose of germicidal energy has been delivered in as little as one second.
The development of the QIKcap Disinfection Device and QIKcap is designed to address the continued risk of bloodstream infections (BSI) and hospital onset bacteremia (HOB), which is any positive blood culture obtained 48 hours after admission. In the 2023 Hospital Safety Grade data that was released on May 3, 2023 by The Leapfrog Group, healthcare-associated infections (HAIs) spiked to a 5-year high in U.S. hospitals during the COVID-19 pandemic and remain high. The report noted that the average CLABSI standard infection ratio increased by 60%. HAIs including Methicillin-resistant Staphylococcus aureus (MRSA), central line bloodstream infections (CLABSI) and catheter-associated urinary tract infections (CAUTI) increase the length of hospitalization stays, add to costs and are the leading causes of death in the U.S.
This novel use of Intellego’s photochromic ink as an ingredient in a medical device is a first for the Swedish company that is best known for its product line, UVC Dosimeters. Used by OEMs, in academic research and in healthcare facilities around the world, UVC Dosimeters are the most trusted and reliable single-use UV indicators cards that provide visible measurement of germicidal ultraviolet energy delivered to surfaces.
According to Claes Lindahl, CEO of Intellego Technologies, “We are excited about the opportunity to expand the application of our proprietary ink technology in new and innovative ways to provide visible evidence of successful UV irradiation. Our partnership with HAI Solutions demonstrates our commitment to life-saving technologies and promoting the safety, efficacy and efficiency of ultraviolet disinfection applications.”
"We are thrilled to announce our new strategic partnership with Intellego Technologies,” said Nicholas Perrenoud, CEO of HAI Solutions. “By working together, we will be able to leverage our respective resources and capabilities to drive innovation, create new opportunities, and deliver even greater value to our stakeholders. We look forward to a successful and mutually beneficial partnership with Intellego."
About Intellego Technologies
Intellego Technologies is a research and development company, headquartered in Solna, Sweden. Founded in 2011, Intellego has grown to become the global leader in colorimetric indicators that are utilized worldwide to visually validate the dose of ultraviolet irradiation delivered to surfaces. Through its patented photochromic ink technology, Intellego manufactures standard and customized indicators that make the benefits of germicidal ultraviolet light visible and promotes the safe, effective and efficient use of UV applications. Intellego’s products support better outcomes with ultraviolet devices in healthcare, food and beverage manufacturing, environmental services, and more. For more information, visit Intellego-Technologies.com and UVCdosimeters.com.
About HAI Solutions
Based in Santa Barbara, CA, HAI Solutions is developing a novel and diverse platform of innovative intravenous therapy solutions targeting IV contamination which occurs in challenging medical segments like the Operating Room, Intensive Care Unit and Emergency Room. Founded in 2015, HAI Solutions believes in protecting every patient by advancing clinical care across the healthcare spectrum. For more information, please visit www.HAI-Solutions.com or Twitter @HAISolutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005235/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom